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Abstract
Background: Solid tumors are often poorly vascularized, with cells that can be 100 μm away from blood vessels. These 
distant cells get less oxygen and nutrients and are exposed to lower doses of chemotherapeutic agents. As gap 
junctions allow the passage of small molecules between cells, we tested the possibility that the chemotherapeutic 
agent gemcitabine can diffuse through gap junctions in solid tumors.
Results: We first showed with a dye transfer assay that the glioblastoma and the osteosarcoma cells used in this study 
have functional gap junctions. These cells were genetically engineered to express the herpes simplex virus thymidine 
kinase (TK), and induced a "bystander effect" as demonstrated by the killing of TK-negative cells in presence of the 
nucleoside analogue ganciclovir (GCV). The ability of gemcitabine to induce a similar bystander effect was then tested 
by mixing cells treated with 3 μM gemcitabine for 24 hours with untreated cells at different ratios. In all cell lines tested, 
bystander cells were killed with ratios containing as low as 5% treated cells, and this toxic effect was reduced in 
presence of α-glycyrrhetinic acid (AGA), a specific gap junction inhibitor. We also showed that a 2- or a 24-hour 
gemcitabine treatment was more efficient to inhibit the growth of spheroids with functional gap junctions as 
compared to the same treatment made in presence of AGA. Finally, after a 24-hour gemcitabine treatment, the cell 
viability in spheroids was reduced by 92% as opposed to 51% in presence of AGA.
Conclusion: These results indicate that gemcitabine-mediated toxicity can diffuse through gap junctions, and they 
suggest that gemcitabine treatment could be more efficient for treating solid tumors that display gap junctions. The 
presence of these cellular channels could be used to predict the responsiveness to this nucleoside analogue therapy.
Introduction
Nucleoside analogues are drugs commonly used in the
clinic as antiviral and anticancer agents. Gemcitabine (2',
2'-difluorodeoxycytidine, dFdC; Gemzar®) is a pyrimidine
analogue that has a well established place in the treat-
ment of several types of solid tumors; it is indicated as a
single agent for the treatment of metastatic pancreatic
cancer and, in combination regimens, for the treatment
of non-small cell lung carcinoma, ovarian and breast can-
cer [1]. The use of gemcitabine is currently being tested in
bladder cancer, mesothelioma and head and neck cancer;
there are also promising results with the combination of
gemcitabine and radiation therapy for the treatment of
glioblastoma [1-4].
Gemcitabine enters cells by interacting with transmem-
brane glycoproteins that control the inward/outward flow
of natural nucleosides. The human nucleoside transport-
ers (hNT) are divided into two groups: the equilibrative
(hENT) and the concentrative (hCNT) types [5]. Gemcit-
abine is a good permeant for hENT1, hENT2, hCNT1
and hCNT3. However, hENT1 seems to be the major
gemcitabine transporter [5-9].
After its entry into the cell, gemcitabine is converted by
the deoxycytidine kinase (dCK) into 2',2'-difluorodeoxy-
cytidine monophosphate which becomes subsequently
phosphorylated to the cytotoxic 5'-diphosphate and 5'-
triphosphate derivatives by pyrimidine monophosphate
and diphosphate kinases. The diphosphate molecule is
capable of inhibiting the ribonucleotide reductase (RR)
directly; on the other hand the triphosphate molecule is
incorporated into DNA and RNA, and affects their syn-
thesis by chain termination [10-12]. The dCK has a
higher affinity for gemcitabine than other substrates
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which results in a more efficient intracellular drug accu-
mulation and toxicity [13]. The above scenario is sup-
ported by in vitro studies that suggest a correlation
between resistance to gemcitabine and the expression
level of hENT1, dCK and RR [14]. In addition, patients
with non-small cell lung carcinoma and pancreatic can-
cer that expressed high levels of hENT1 responded better
to gemcitabine and survived longer [15-18]. In one study,
hCNT3 was also a predictive survival factor after adju-
vant gemcitabine therapy in resected pancreatic adeno-
carcinoma [18].
One limitation to gemcitabine efficacy, that is common
to other chemotherapeutic agents, is its poor penetration
in solid tumors [19-21]. Gemcitabine is normally admin-
istered systemically and reaches the cancer site through
blood vessels. The vasculature in solid tumors is poorly
organized as compared to normal tissues. Neoplastic cells
can be as far as 100 μm distant from the nearest blood
vessel, and this results in a gradient distribution of the
chemotherapeutic agent. Therefore, tumor cells that are
far from the blood supply not only are less exposed to the
drug but also tend to be more quiescent due to hypoxia
and lack of nutrients, and are intrinsically less sensitive to
chemotherapy [19,22]. This is illustrated by the lack of
efficacy of gemcitabine treatment in a transgenic mouse
model of pancreatic cancer due to the poor vasculariza-
tion of the tumor [23].
Gap junctions are composed of a family of proteins
called connexins that allow passive diffusion of small
molecules (≤1 kD) between cells. Ions, short peptides and
most second messengers such as cAMP, calcium and
innositol 1,4,5-triphosphate can traffic across these
molecular channels [24]. It is well documented that gan-
ciclovir (GCV) and its phosphorylated metabolites can
diffuse in tumors through gap junctions producing a phe-
nomenon called the "bystander effect" [25,26]. GCV is a
nucleoside analogue that is used primarily as an antiviral
agent but that may turn into an anticancer drug if tumor
cells are engineered to express the herpes simplex virus
thymidine kinase (TK) [26,27].
We hypothesize that gemcitabine and its metabolites
can diffuse through gap junctions in a way that is reminis-
cent of the GCV intercellular diffusion. In this study, we
show that gemcitabine can induce a bystander effect in
glioblastoma and osteosarcoma cells. This effect was
demonstrated in two and three-dimensional culture
models and was blocked by a specific gap junction inhibi-
tor.
Materials and methods
Cell lines and Monolayer Culture
The human glioblastoma cell line U87 (ATCC HTB-14),
and the human osteosarcoma cell lines MNNG/HOS
(ATCC CRL-1547) and MG-63 (ATCC CRL-1427) were
obtained from the American Type Culture Collection.
The glioblastoma SKI-1 cell line was obtained from
Jacques Galipeau (McGill University, Montreal, Canada).
All four cell lines were negative by Hoechst staining for
the presence of mycoplasmas. Cells were cultured in Dul-
becco's Modified Eagle medium (DMEM; Sigma, St-
Louis, MO, USA) supplemented with 10% fetal calf serum
(FCS; PAA laboratories, Etobicoke, Canada) and antibiot-
ics. All cultures were maintained in humidified atmo-
sphere with 5% CO2 in air at 37°C. Cells containing the
GFP/TK gene were generated by retroviral infections
[28], and were cultured as their parental counterparts.
Multicellular Spheroid Culture
Spheroids of SKI-1 and MG-63 cells were generated by
the liquid overlay culture technique as previously
described [29]. Single-cell suspensions (4 × 103 or 2 × 103
cells per well) obtained from exponentially growing
monolayer cultures were seeded in 96-well plates coated
with a thin layer (50 μl per well) of 1.5% agarose solution,
mixed in 1:1 ratio with DMEM. Both cell lines formed
well-rounded, regularly shaped spheroids within 3 days of
static incubation. At this stage, diameters of spheroids
were between 300 and 400 μm.
Cx43 Immunofluorescence
Cells were cultured on glass coverslips in 35-mm dishes
until they reached sub-confluency. Cells were fixed in 4%
paraformaldehyde, permeabilized with 0.2% Triton X-100
and incubated with a primary antibody raised against
Cx43 (1:800; Sigma) followed by an Alexa594-conjugated
goat anti-mouse (1:1000) (Invitrogen). Nuclei were coun-
terstained with Hoechst reagent. Cells were observed
with a Bio-Rad MRC-1024 confocal microscope mounted
on a Nikon Diaphot-TMD.
Gap Junctional Intercellular Communication Assay
In monolayer cultures, gap-junctional coupling was mea-
sured by double-dye flow cytometry as described previ-
ously [28,30]. Briefly, cells were labelled with 3 μM
calcein-AM (acetoxymethyl ester) or 5 μM DiI (Invitro-
gen) diluted in Opti-MEM medium (Invitrogen). SKI-1,
MNNG/HOS and MG-63 cells were plated at 0.6 × 106
cells per cm2, and U87 cells at 0.8 × 106 cells per cm2 to
allow intercellular contact. Next, calcein-loaded cells
were plated on top of the DiI-stained cells at a ratio of
1:10 (donors:recipients). After 6 hours of incubation at
37°C, the cell mixtures were detached and analyzed by
f l o w  c y t o m e t r y .  F l u o r e s c e n c e  w a s  m e a s u r e d  w i t h  a
Coulter EPICS XL-MCL flow cytometer and Expo32
software (Beckman Coulter, Brea, CA). Similar dye trans-
fer experiments were performed with the gap junction
inhibitor α-glycyrrhetinic acid (AGA; Sigma) [31]. Cells
were incubated with AGA at 70 μM 24 hours before theCottin et al. Molecular Cancer 2010, 9:141
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labelling of the cells and during the rest of the experi-
ment. The effect of gemcitabine (kindly provided from
hospital Hôtel-Dieu de Québec) on gap junctional inter-
cellular communication was assessed by incubating cells
with 3 μM gemcitabine 24 hours before the labelling of
the cells and during the rest of the experiment.
Gap junctional intercellular communication was also
assessed in three-dimensional cultures. SKI-1 and MG-63
spheroids grown for 4 days in 96-well plates were labelled
for 1 hour by replacing 50% of culture medium with a 3
μM calcein-AM solution. Twenty spheroids per condition
were then washed with PBS and trypsinized with a 0.25%
or a 0.05% solution of trypsine/EDTA, for SKI-1 and MG-
63 spheroids, respectively. Dissociated cells were pooled,
centrifugated, resuspended in PBS and analyzed for fluo-
r e s c e n c e  b y  fl o w  cy t o m e t ry .  T h i s  e x p e r i m e n t  w a s  a l s o
carried out in presence of 70 μM AGA started 24 hours
before and during labelling.
Gemcitabine Dose Response
Cells were plated in 96-well plates at 103 cells per well and
treated the following day with an increasing concentra-
tion of gemcitabine varying from 0.1 nM to 10 μM for 24
hours. The cytotoxic effect of gemcitabine was deter-
mined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay 3 to 4 days later at the time
untreated cells reached confluency.
TK/GCV, Gemcitabine, Cisplatine and Temozolomide 
Bystander Effect
TK/GCV bystander effect experiment has been described
previously [28,32]. Briefly, 10% or 2% TK-expressing cells
were mixed and plated in 6-well plates with their respec-
tive parental cell lines, at identical concentrations to the
ones used for the gap junctional intercellular communi-
cation assay. The following day, confluent cells were
treated with 10 μM GCV. On day 3, cells were trypsinized
and a 1:100 dilution of the cells was distributed into 96-
well plates in five replicates. Cells were cultured subse-
quently in the presence of GCV for 3 days and cell prolif-
eration was measured using the MTT assay. A final
concentration of 0.5 mg/ml of MTT was added to wells
and the plates were incubated at 37°C for 2 hours. After
medium removal, 150 μl of dimethyl sulfoxide was added
and the plates were gently shaken for 10 min to dissolve
the formazan blue crystals. The absorbance was then
measured at 595 nm with a microplate reader (Tecan,
Research Triangle Park, NC).
For the gemcitabine bystander effect experiments, cells
were plated in 6-well plates at concentrations identical to
those used for the dye transfer. The following day, conflu-
ent cells were left untreated or were treated with 3 μM
gemcitabine for 24 hours. On day 3, treated and
untreated cells were mixed at different ratios containing
1, 5, 10 or 50% treated cells, and plated in 24-well plates
in order to allow cell-cell contact for 24 hours. The next
day, cells were detached and a 1:100 dilution of the cells
was disposed in 96-well plates, and cultured for 3 days.
Cell proliferation was measured by the MTT assay at day
7. Experiments were also carried out in presence of 70
μM AGA. Similar experiments were performed with 10
μM cisplatine and 1 mM temozolomide.
Gemcitabine Cytotoxicity in Spheroids
Three days after cell seeding, SKI-1 and MG-63 spheroids
were treated with 3 μM gemcitabine for 2 hours or 24
hours in presence or absence of AGA. After the removal
of gemcitabine, the spheroids were grown for 6 days and
the gemcitabine cytotoxic effect was evaluated by mea-
suring the diameter of each spheroid with a calibrated
TE2000 microscope (Nikon, Melville, NY) using Metavue
software (Molecular Devices, Sunnyvale, CA). AGA
treatment was kept until diameters were measured.
A modified acid phosphatase assay was used to deter-
mine cell viability in spheroids [33]. Six days after gemcit-
abine treatment, each individual spheroid was transferred
with supernatant into standard 96-well plates and centri-
fuged for 10 min at 1, 000 × g. The supernatant was then
carefully removed and spheroids were washed with PBS.
Plates were once again centrifuged and the supernatant
discarded. Next, 100 μl of PBS with 100 μl of the assay
buffer containing 0.1 M sodium acetate, 0.1% Triton X-
100 and 5 mM p-nitrophenyl phosphate (Sigma) was
added in each well and incubated for 90 min at 37°C.
Finally, 10 μl of 1 N NaOH was added to each well, and
the absorbance was measured at 415 nm.
Results
Gap junction expression and functionality in glioblastoma 
and osteosarcoma cells
The role of gap junctions was tested in two types of can-
cer that have been previously shown to be responsive to
gemcitabine [2-4,34,35]. First, we have analyzed the con-
nexin 43 (Cx43) expression profile in two glioblastoma
and two osteosarcoma cell lines. Figure 1A shows that in
agreement with our previous report [28], SKI-1 and U87
glioblastoma cells predominantly express Cx43 in cyto-
plasmic perinuclear compartments. Instead, Cx43 was
localized on the plasma membrane as streaks and spots
representative of gap-junctional plaques in the osteosar-
coma cell line MNNG/HOS. Like SKI-I and U87 cells,
MG-63 cells had Cx43 located mainly in cytoplasmic
areas, with very little Cx43 at the cell surface (Figure 1A).
Next, the gap junctional intercellular communication
was evaluated in these four cell lines by a double-dye flow
cytometry assay using ratios of 10% calcein-AM-loaded
cells and 90% Dil-labelled cells. The percentage diffusion
of calcein into Dil-labelled cells in these experiments wasCottin et al. Molecular Cancer 2010, 9:141
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87.3% for SKI-1 cells and 81.5% for U87 cells. The
MNNG/HOS cells were also extensively coupled since
calcein diffused into 83.5% DiI-labelled cells. Coupling
was less pronounced in MG-63 cells as calcein diffusion
reached 59.9% of the neighboring cells. Similar experi-
ments were performed in presence of AGA, a specific gap
junction inhibitor; dye transfer in MNNG/HOS and SKI-
1 cells were completely abolished in these conditions.
Treatment of U87 and MG-63 cells with AGA inhibited
the gap junction intercellular communication by 50% and
17%, respectively (Figure 1B). Once we have ascertained
that the four cell lines used in this study possess highly
functional gap junctions, we have tested their ability to
mediate a bystander effect
Diffusion of phosphorylated GCV was studied in the
SKI-1 and MNNG/HOS cell lines. First, stable cells
expressing GFP/TK were derived from each parental cell
line by retroviral gene delivery as described previously
[28]. Cell viability was measured after mixing 2% and 10%
TK-expressing cells with their parental counterparts fol-
lowed by GCV treatment. Cell survival was only 40% and
41% of the control in mixtures that contained 10% and 2%
TK-expressing SKI-1 cells, respectively (Figure 1C). The
cell viability of MNNG/HOS cells was 27.6% and 44.6% in
the mixtures that included 10% and 2% TK-expressing
cells, respectively (Figure 1D). Our results showed that
both cell lines were able to mediate a strong bystander
effect, most likely due to the transfer of phosphorylated
Figure 1 Cx43 expression and functionality in glioblastoma and osteosarcoma cell lines. A. Immunofluorescence of Cx43 shown by confocal 
microscopy; scale bar: 20 μm: B. Intercellular communication measured by double dye flow cytometry. The percentage of communicating cells rep-
resents the percentage of DiI-stained cells that picked up calcein from calcein-loaded cells in presence (open bars) or not of AGA (red bars). Each value 
is the mean ± s.d. of triplicates of at least three separate experiments. Statistical significance between untreated and AGA-treated cells was evaluated 
by a Student t-test (*, p < 0.05; **, p < 0.01). Bystander effect of the thymidine kinase/ganciclovir strategy: C. In SKI-1 glioma cells. D. In MNNG/HOS 
osteosarcoma cells. Data are the means ± S.D. of five replicates of three separate experiments.
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GCV from TK-expressing cells into TK-negative
bystander cells.
Gemcitabine cytotoxicity
Before testing the gemcitabine-mediated bystander
effect, the sensitivity to a 24-hour drug treatment was
assessed in the four gap junction-positive cell lines. All
cell lines were quite sensitive to gemcitabine, with con-
centrations that inhibited cell proliferation by 50% rang-
ing from 3.5 to 13 nM (Figure 2). A dose of 3 μM
gemcitabine, that is achievable in the serum of treated
patients, was chosen for the following experiments
[36,37].
Inhibition of gap junctional intercellular communication by 
gemcitabine
The effect of gemcitabine on gap junction functionality
was examined because its mechanism of action involves
the inhibition of DNA and RNA synthesis [1], and Cx43
has a short half-life [24,38]. Calcein diffusion was mea-
sured in both glioblastoma and osteosarcoma cell lines
after gemcitabine treatment. Gap junction-mediated dye
transfer was inhibited in all cell lines tested, although at
different intensities. Reductions of 38.5%, 55.4% and
32.1% were observed in SKI-1, U87 and MG-63 cell lines,
respectively. The inhibition was less pronounced in
MNNG/HOS cells, with a 14.3% reduction in calcein
transfer obtained after gemcitabine treatment (Figure 3).
Gemcitabine bystander effect
The bystander effect mediated by gemcitabine was evalu-
ated in the four cell lines characterized previously. Cells
that had been treated with gemcitabine were mixed at dif-
ferent ratios with their untreated counterparts and plated
at confluency (after the 24-hour gemcitabine treatment,
the number of cells in the treated wells was 50% lower as
compared to the untreated wells; treated and untreated
cells were equally viable as measured by trypan blue
exclusion). After 1 day of contact, cells were diluted and
cultured until their viability was measured (Figure 4A
illustrates the experimental design). The experiment was
also performed in presence of AGA in order to evaluate
the involvement of gap-junctions in the bystander effect.
All cell lines showed a strong bystander effect since as lit-
tle as 1% treated cells were able to affect the viability of
untreated cells. At this ratio (1/100), the viability was
within the 88%-51% range. The viability dropped to even
lower levels when the percentage of treated cells used in
the mixtures increased. As little as 4% live cells were
obtained with a 1/1 treated/untreated ratio in SKI-1 cells.
Similar results were achieved with MG-63 cells (7% at 1/1
ratio). The bystander effect was most effective in MG-63
cells: the viability at the 1/100 ratio was 51%, and it
decreased to 7% in the 1/20 ratio. In the four cell lines, the
bystander effect was significantly inhibited in the pres-
ence of AGA at ratios containing 1/20 and 1/10 gemcit-
abine treated cells. AGA was also capable of inhibiting
the bystander effect in U87 and MG-63 cells when the 1/
100 ratio was adopted (Figure 4B). These results indi-
cated that the osteosarcoma and glioblastoma cells are
susceptible to a gemcitabine-mediated bystander effect
that can be blocked by the gap junction inhibitor AGA.
On the contrary, there was no gemcitabine-mediated
bystander effect with HeLa cells that are devoid of gap
junction (data not shown), and there was also no
bystander effect with the chemotherapeutic agents cispl-
Figure 3 Inhibiton of dye transfer by gemcitabine. The transfer of 
calcein between cells was evaluated after a 24-hour treatment with 3 
μM gemcitabine. Data are the means ± S.D. of three independent ex-
periments. Statistical significance for the inhibition of gap junction was 
evaluated by a Student t-test (*, p < 0.05; **, p < 0.01).
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Figure 2 Gemcitabine cytotoxicity on glioblastoma and osteosar-
coma cells. Cell survival was measured 4 days after a 24-hour gemcit-
abine treatment. Cell survival was expressed in comparison to 
untreated cells. Each value is the mean ± S.D. of five replicates.
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Figure 4 Bystander effect of gemcitabine in glioblastoma and osteosarcoma cell lines. A. Experimental design of the bystander effect assay: B. 
Bystander effect of gemcitabine with (blue bars) or without AGA (red bars). Data are the means ± S.D. of five replicates of at least three separate ex-
periments. Statistical significance between untreated and AGA-treated cells was evaluated by a Student t-test (*, p < 0.05; **, p < 0.01): C. Absence of 
cisplatine and temozolomide bystander effect in SKI-1 and MNNG/HOS, respectively.
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atine and temozolomide tested on SKI-1 and MNNG/
HOS cells (Figure 4C).
Gap junctional intercellular communication in spheroids
A three-dimensional spheroid culture system was set-up
to test the gemcitabine bystander effect in a physiologi-
cally more relevant in vitro model. First, the diffusion of
calcein was evaluated in SKI-1 and MG-63 multicellular
tumor spheroids. After one hour labelling with calcein-
AM, spheroids were dissociated into single cells and were
analyzed for fluorescence by flow cytometry. One sharp
highly fluorescent peak was obtained indicating that cal-
cein had diffused well in the spheroid model and that cells
had been homogenously labelled. When the experiment
was performed in presence of AGA, cells were heteroge-
neously labelled and has a mean fluorescence intensity
that was ten times lower as compared to untreated con-
trol cells (Figure 5). These results suggested that gap
junctions were functional in the spheroid model and that
they could be inhibited by AGA treatment.
Gemcitabine effect on spheroid growth
After having demonstrated that gemcitabine induces a
gap junction-mediated bystander effect in standard two-
dimensional cell culture systems, we have tested if this
effect was also present in tumor spheroids. Gemcitabine
treatment for 2 hours was sufficient to inhibit the growth
of SKI-1 and MG-63 spheroids by 19% and 27%, respec-
tively (mean diameter ± SD for SKI-1 cells: untreated, 609
± 33 nm; treated, 497 ± 11 nm; mean diameter ± SD for
MG-63 cells: untreated, 483 ± 15 nm; treated, 357 ± 8
nm). The growth inhibition was slightly increased if the
gemcitabine treatment lasted 24 hours. Indeed, the vol-
umes were reduced by 23% and 28% in SKI-1 and MG-63
spheroids, respectively (mean diameter ± SD for treated
cells: 471 ± 13 nm in SKI-1 cells and 351 ± 12 nm in MG-
63 cells). The effect of gemcitabine on spheroids was
abolished if the same experiment was performed in pres-
ence of AGA, (Figure 6A). These results suggested that
functional gap junctions mediate the cytotoxicity of gem-
citabine in three-dimensional in vitro models of glioblas-
toma and osteosarcoma.
The effect of gemcitabine on spheroids was next tested
with the acid phosphatase viability assay since the mea-
sure of spheroid diameters does not distinguish between
dead and live cells. Six days after a 24-hour gemcitabine
treatment, the cell viability of SKI-1 spheroids was
reduced by 92%. In presence of AGA, the viability was
only reduced by 51% (Figure 6B). These results further
support a role for gap junctions in the gemcitabine-medi-
ated toxicity in three-dimensional in vitro models and are
in agreement with the data obtained by measuring spher-
oid diameters.
Discussion
In this study, we have tested the hypothesis that the che-
motherapeutic agent gemcitabine could be more efficient
to treat tumors displaying functional gap junctions. We
have shown in glioblastoma as well as in osteosarcoma
that gemcitabine-treated cells could kill untreated cells in
a gap junction-dependent manner.
Figure 5 Dye transfer in multicellular spheroids. The transfer of cal-
cein was measured in SKI-1 and MG-63 spheroids in absence (grey ar-
ea) or presence (black line) of AGA. The plot presented for each cell line 
is representative of an experiment performed three times.
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Figure 6 Gemcitabine cytotoxic effect on spheroids. A. Spheroid 
diameters were measured 6 days after gemcitabine treatment for 2 
hours or 24 hours with (blue bars) or without AGA (red bars). Spheroid 
diameters are expressed as percentage of untreated spheroids with or 
without AGA. Data are the means of five replicates ± S.D. of one repre-
sentative experiment performed twice. Statistical significance be-
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nificance between untreated (-) and AGA-treated cells was evaluated 
by a Student t-test (***, p < 0.0001).
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Both glioblastoma cell lines and MG-63 cells had Cx43
mainly located in cytoplasmic areas with only few
plaques at the cell surface. Despite this aberrant localiza-
tion, these cells could transfer calcein as efficiently as
MNNG/HOS cells that had a high level of Cx43 assem-
bled into punctate gap junction plaques (Figures 1A and
1B). It is conceivable that other connexin family members
could contribute to gap junctional intercellular commu-
nication. However, this possibility would not affect the
conclusion of our study that links the functionality of gap
junctions and not its composition to the gemcitabine-
induced bystander effect.
A strong bystander effect that was responsive to AGA
was observed in monolayer cultures in cell mixtures con-
taining 1%, 5% and 10% gemcitabine-treated cells (1/100,
1/20 and 1/10 ratios). On the contrary, except for U87
cells, AGA had no effect on the bystander effect if cell
mixtures contained 50% (1/1) gemcitabine-treated cells.
These results suggest that the bystander effect had a dif-
ferent mechanism in low versus high ratios of gemcit-
abine-treated cells in this experimental set-up. One likely
explanation is that hENT1 could transport gemcitabine
out of the treated cells making it available in the media to
be picked up by untreated cells. This bystander mecha-
nism would only be predominant at high ratios of gemcit-
abine-treated cells that produce a cytotoxic concentration
in the cell culture medium. It is worth noting that AGA
decreased the cytotoxic effect of gemcitabine in 100%
treated U87 cells, and a similar reduction is also observed
at the 50% cell ratio (Figure 4B).
At this point, we cannot completely discard that a cellu-
lar toxic compound triggered by gemcitabine treatment
could diffuse through gap junctions and mediate the
bystander effect. However, we favor the diffusion of gem-
citabine and its metabolites because it resembles a well
described bystander effect mechanism adopted by
another nucleoside analogue, GCV [25,26]. Furthermore,
two other non-nucleoside chemotherapeutic agents, cis-
platin and temozolomide, do not generate a bystander
effect (Figure 4C).
There are major differences between the vasculature of
normal and that of malignant tissues. Blood vessels are
well organized and in sufficient number to irrigate all
cells in normal tissues. On the other hand, blood vessels
are disorganized in tumors; they have arterio-venous
shunts and incomplete vessel walls, leading to a sluggish
and irregular blood flow. Cells that are away from blood
vessels are not reached by effective doses of chemothera-
peutic agents, a situation that cannot be mimicked in
monolayer cultures [19,22]. The spheroid model used in
this study is more clinically relevant in comparison to the
two-dimensional culture system. This model is well
established and commonly used to assess the efficacy of
anticancer drugs. It displays gradients of nutrients and
oxygen and cell proliferation occurs from the outer to the
inner part of the spheroid [19,29,39]. As expected, cells in
spheroids are more resistant to chemotherapy, and thus
reflect closer the clinical situation (Figures 2 and 6)
[21,35].
Hypoxia is commonly found in tumors due to the large
d i s t a n c e  t h a t  s e p a r a t e  s o m e  n e o p l a s t i c  c e l l s  f r o m  t h e
microvasculature. It is often associated with an aggressive
tumor phenotype and resistance to radiation therapy and
chemotherapy. Hypoxia inducible factor-1 (HIF-1) is a
transcription factor expressed upon hypoxic conditions
that regulates genes for their adaptation to a low oxygen
environment [40]. As it has been reported in endothelial
cells, HIF-1 is capable of repressing hENT1 during
hypoxia [41]: thus we can presume that hENT1 is poorly
expressed in tumor cells that are away from blood vessels.
However, these cells could still be killed by gemcitabine if
tumors display gap junctional intercellular communica-
tion. Cells close to blood vessels would pick-up gemcit-
abine using hENT1, and the drug-induced toxicity would
diffuse to distant cells through gap junctions.
Down-regulation of connexin expression has been
observed in certain tumors [42]. However, this biological
phenomenon is not universal: in prostate cancer the
d e c r e a s e  i n  C x 4 3  o c c u r s  i n  l a t e  s t a g e s  a n d  n o t  i n  t h e
benign stages [43]. Also, Cx26 is up-regulated in
squamous cell lung carcinoma, breast cancer, and papil-
lary and follicular thyroid cancers [44-46]. This view is
supported by our recent finding that Cx43 expression is
preserved in 77% of a large number of glioblastoma
tumor samples, and that gap junctions are functional in
primary glioblastoma cultures (unpublished data). For
the other cancer types with less gap junctions, pharmaco-
logical strategies that increase connexin expression could
be combined to gemcitabine treatment [47].
Conclusion
This paper shows for the first time that the diffusion and
cytotoxicity of a drug that is commonly used in cancer
therapy (gemcitabine) is directly dependent on gap junc-
tion expression in tumor cells. We propose that the pres-
e n c e  o f  ga p  j u n c t i o n s  i n  t u m o r  c e l l s  c o u l d  be  us ed  t o
predict the responsiveness to the nucleoside analogue
therapy. The results of this study may have strong impli-
cations in the clinical context of the various types of solid
tumors for which gemcitabine is used alone or in combi-
nation.
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